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Abstract
Background:Theprevalence of nausea and vomiting after receipt of intrathecalmethotrexate (IT-
MTX) in pediatric oncology patients is unknown.
Methods: Patients (4–18 years) about to receive IT-MTX were eligible to participate in this
prospective, observational study. Patients received antiemetics as prescribed by their clini-
cal team. Nausea severity (patient-assessed), timing of emetic episodes, and administration
of antiemetics were recorded beginning immediately prior to IT-MTX administration, for the
next 24 hr (acute phase), and for a maximum of 7 additional days (delayed phase). Complete
chemotherapy-induced nausea and vomiting (CINV) control was defined as no emetic episodes
and no nausea.
Results:One hundred patients consented to participate in this study; 70 provided evaluable data
(meanage: 8.3 years; range: 4.1–17.6).Most (94%) receivedpropofol-containing anesthesia for IT-
MTX administration. Most (89%) received a 5-HT3 antagonist prior to IT-MTX. During the acute
phase, 36 children (51%) experienced complete CINV control, 67 (96%) complete vomiting con-
trol, and 36 (51%) complete nausea control. Severe acute phase nausea was reported by 12 chil-
dren (17%). During the delayed phase, 35 patients (50%) experienced complete CINV control,
60 (86%) complete vomiting control, and 36 (51%) complete nausea control. Severe nausea was
reported in the delayed phase by 27 (39%) patients.
Conclusions:Most pediatric patients who received IT-MTX and prophylaxis with ondansetron or
granisetron experienced complete acute and delayed vomiting control. However, nausea control
was poor and severe nausea was reported by many children. Effective interventions to control
nausea are needed.
K EYWORDS
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1 INTRODUCTION
Chemotherapy emetogenicity is the primary factor considered when
selecting chemotherapy-induced nausea and vomiting (CINV) prophy-
laxis for children.1 Yet, the CINV experience of children and ado-
lescents receiving specific chemotherapy is seldom documented. To
date, no publications have evaluated nausea and vomiting in pedi-
atric patients exclusively receiving intrathecal methotrexate (IT-MTX),
a required component of acute lymphoblastic leukemia (ALL) treat-
Abbreviations: ALL, acute lymphoblastic leukemia; CIN, chemotherapy-induced nausea;
CINV, chemotherapy-induced nausea and vomiting; CIV, chemotherapy-induced vomiting;
IT-MTX, intrathecal methotrexate; IV, intravenous; PeNAT, Pediatric Nausea Assessment
Tool; PO, oral; TIT, triple intrathecal therapy
ment.Without this information, it is difficult to apply the recommenda-
tions of clinical practice guidelines for the prevention ofCINV2,3 and to
optimizeCINVcontrol. In this study,weusedavalidated, pediatric nau-
sea self-assessment measure the (PeNAT)4 to describe the prevalence
of acute and delayed CINV in pediatric patients with ALL receiving
IT-MTX.
2 METHODS
This prospective, single-center, observational study was approved by
the Research Ethics Board at SickKids. Each patient or their guardian
provided informed consent or assent to study participation.
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2.1 Patients
Patients 4–18 years of age who were about to receive IT-MTX within
the second or later maintenance cycle of an ALL treatment protocol,
were English-speaking with an English-speaking parent, and had no
physical or cognitive impairment that precluded the use of the PeNAT4
were eligible to participate. Patients planned to receive chemotherapy
other than oral (PO) 6-mercaptopurine, POprednisone, or dexametha-
sone or intravenous (IV) vincristine during the week following the IT-
MTX dose were excluded. Patients received antiemetics as ordered by
the clinical team. Patients participated only once.
2.2 Data collection
Patient’s demographic data, chemotherapy and antiemetic agents
given in hospital or clinic during the study period, and medication
given during the lumbar puncture procedurewere abstracted from the
health record. Patients or their parent were asked if they had a his-
tory of uncontrolled chemotherapy-induced vomiting (CIV) defined as
a previous hospital admission or the prolongation of a hospital admis-
sion for management of vomiting following chemotherapy administra-
tion. Antiemeticmedication given at home during the study periodwas
recorded by the patient or parent on a diary provided.
2.3 CINV assessment
Patients and guardians recorded the patient’s PeNAT scores and the
time of each vomit and retch on the provided diary. Vomiting was
defined as the expulsion of any stomach contents by themouth. Retch-
ing was defined as an attempt to vomit that is not productive of any
stomach contents.
Amember of the study teamadministered the PeNAT to the patient
once before IT-MTX administration and asked the patient and their
parent to report the patient’s experience with nausea, vomiting, and
retching over the previous 24 hr. The parent and patient were then
instructed on the administration of the PeNAT and on the completion
of the diary. Diaries were to be completed on each day of the acute and
delayed phases. The acute phase startedwith the administration of the
IT-MTX dose within the study period and continued for 24 hr or, if vin-
cristinewas administered, for 24 hr after the administration of the vin-
cristine dose. The delayed phase started when the acute phase ended
andcontinued for7days (168hr).During theacute anddelayedphases,
each patient was asked to rank the severity of his or her nausea atmin-
imum twice daily (on rising in the morning and at bedtime) plus at any
other time that they felt nauseated or their guardian believed them to
feel nauseated. If the patient could not record their data on the diary or
chose not to, guardians were instructed to record the nausea severity
as ranked by their child without interpretation.
Amemberof the study teamcontactedeach familyup to three times
during the study period to answer any questions and to remind them to
complete and return the diary.
2.4 Statistical analysis
The primary endpoint of this descriptive study was complete con-
trol of CINV during the acute phase (Table 1). A sample size of
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Assessed for eligibility (n= 204)
Excluded (n=104)
Did not meet inclusion 
criteria (n=60)
Declined to participate 
(n=24)
Logistical barriers to 
recruitment (n=20)
Acute CINV outcomes 
analysed: (n=70)
CINV diary incomplete 
or not returned  (n=18)
Consented to participate (n=100)Allocation
Analysis
Follow-Up
Enrollment
Delayed CINV outcomes 
analysed: (n=70)
CINV diary incomplete 
or not returned (n=18)
Did not meet study 
eligibility criteria (n=8)
Withdrew from study 
(n=3)
Child unable to use 
PeNAT (n=1)
F IGURE 1 Study flow diagram
100 patients was chosen to permit the description of CINV prevalence
with confidence and allowed for an unknown proportion of children
whomight not provide evaluable data. The secondary study endpoints
were complete CIV and chemotherapy-induced nausea (CIN) control
during the acute phase and complete CINV, CIV, and CIN control dur-
ing the delayed and overall phases. The overall phase is comprised of
both the acute and delayed phases. The proportions of patients who
experienced complete, partial, and uncontrolled acute CINV control in
the acute, delayed, and overall phases were described.
Differences between groups were assessed using chi-square or
nonparametric analyses as appropriate (SAS Enterprise Guide 6.100,
SAS Institute Inc., Cary, NC, USA).
3 RESULTS
3.1 Patients
Two hundred four patients were screened fromMay 7, 2012, through
October 2, 2015, and 124 were invited to participate in the study.
Of the 88 patients who initiated the study, 70 returned completed
diaries. Patients who did not return completed diaries did not differ
from patients who did return completed diaries in terms of mean age
(7.6 ± 4.2 vs. 8.3 ± 3.3 years; P = 0.14) or sex (female/male: 5/13 vs.
19/51; P= 0.23). The study flow diagram is presented in Figure 1.
Patient and treatment characteristics are presented in Table 2.
Most patients received ondansetron or granisetron as CINV prophy-
laxis prior to IT-MTX (62/70), propofol as anesthetic (67/70), and vin-
cristine (69/70) on the same day of IT-MTX. Approximately one-third
of patients received antiemetic agents (ondansetron/granisetron: 18;
dimenhydrinate: 2; nabilone: 1) later in the acute phase. Almost all
patients received PO 6-mercaptopurine (69/70) and POMTX (68/70)
during the delayed phase.
3.2 CINVControl
CINV, CIV, and CIN control rates reported in the acute, delayed,
and overall phases are presented in Table 3. During the acute phase,
36 patients (51%) experienced complete CINV control, 67 (96%) com-
plete vomiting control, and 36 (51%) complete nausea control. Severe
acute nausea was reported by 12 children (17%). In the delayed phase,
35 children (50%) experienced complete CINV control, 60 (86%) com-
plete vomiting control, and 36 (51%) complete nausea control. Severe
nausea was reported in the delayed phase by 27 (39%) children.
4 DISCUSSION
In this prospective study, we found that pediatric patients who
received ondansetron or granisetron prior to IT-MTX experienced
excellent vomiting control in the acute phase. Acute phase nausea,
however, was less well controlled and poor acute CINV control was
primarily driven by nausea. This pattern persisted in the delayed and
overall phases.
Nausea and vomiting following intrathecal chemotherapy admin-
istration may stem from the intrathecal chemotherapy itself, the
act of lumbar puncture and concurrent medication including anes-
thetic agents, analgesics, and IV/PO chemotherapy. Five studies
have described vomiting in pediatric patients following intrathecal
chemotherapy administration.5–9 One randomized patients to receive
midazolam plus one of four possible combinations given once prior to
administration of unspecified intrathecal chemotherapy: fentanyl or
placebo plus ondansetron or placebo.9 All children received propo-
fol. Patients who received ondansetron reported fewer episodes of
vomiting or retching during the 12 hr after lumbar puncture (over-
all reduction of 4.664; P < 0.0001). Three studies evaluated vomit-
ing after administration of triple intrathecal therapy (TIT; cytarabine,
MTX, and hydrocortisone) to pediatric patients.6,7,10 In the first, vom-
iting was evaluated in a subset of 16 patients after 27 doses of TIT
where no antiemetic prophylaxis had been given.10 The mean number
of vomiting episodes reported in the 7 days after TIT administration
in this subset was 8.3 ± 12.2. The same authors later described vomit-
ing control in 63 patients aged 1–17 years who received TIT.6 Patients
received either no antiemetic prophylaxis or ondansetron IV/PO. No
general anesthetic agents or opioids were administered. Most (78%)
of the patients who received no antiemetic prophylaxis vomited dur-
ing the week following TIT administration, whereas this rate was 31
and44% inpatientswho received IVandPOondansetron, respectively.
Vomiting was described as typically beginning 3–4 hr after TIT admin-
istration and rarely lasting longer than 24 hr. Lastly, Parker et al. have
described vomiting control following 146 intrathecal chemotherapy
doses in 26pediatric patients randomized to receive placebo, low-dose
IV ondansetron, or high-dose IV ondansetron.7 Most (22/26) patients
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TABLE 2 Characteristics of the 70 evaluable patients and their treatment
Patient Characteristics
Mean age, years (range) 8.3 (4.1–17.6)
Sex, no. of patients (male:female) 51:19
History of uncontrolled CIV, no. of patients (%) 13 (19)
Anticipatory nausea or vomiting prior to IT-MTX, no. of patients (%) 12 (17)
Treatment Characteristics
Receipt of vincristine, no. of patients 69
Receipt of concurrent corticosteroid, no. of patients
Prednisone 32
Dexamethasone 30
None 8
Anesthetic administered, no. of patients
Propofol 52
Propofol+ other 15
Other 3
Antiemetic administered before IT-MTX, no. of patients
Ondansetron/granisetron 62
Nonea 8
Antiemetic administered during the delayed phase, no. of patients
Ondansetron/granisetron 11
Dimenhydrinate 3
Dexamethasone 1
None 55
IT-MTX, intrathecal methotrexate; CIV, chemotherapy-induced vomiting.
aOf the eight childrenwho did not receive an antiemetic, seven were given ondansetron or granisetron immediately after the procedure.
TABLE 3 Nausea and vomiting control reported by 70 children
receiving IT-MTX
Level of control CIV CIN CINV
Acute phase, no. of patients (%)
Complete control 67 (96) 36 (51) 36 (51)
Partial control 3 (4) 22 (31) 22 (31)
Uncontrolled 0 (0) 12 (17) 12 (17)
Delayed phase, no. of patients (%)
Complete control 60 (86) 36 (51) 35 (50)
Partial control 9 (13) 7 (10) 8 (11)
Uncontrolled 1 (1) 27 (39) 27 (39)
Overall phase, no. of patients (%)
Complete control 40 (57) 26 (37) 26 (37)
Partial control 15 (21) 13 (19) 13 (19)
Uncontrolled 15 (21) 31 (44) 31 (44)
received TIT and most doses were accompanied by midazolam plus
ketamine. The proportions of patients who did not vomit during the
48 hr after intrathecal chemotherapy and who received placebo, low-
dose ondansetron, or high-dose ondansetron were 37, 73, and 86%,
respectively.
Traivaree et al.conducted a randomized, cross-over, double-blind
trial to evaluate a single dexamethasone dose to prevent vomiting
associated with intrathecal chemotherapy in 33 children (aged 2.2–
14.2 years) given ketamine sedation.8 All but one patient received
IT-MTX. In the 24 hr after intrathecal chemotherapy administration,
vomiting rates in the dexamethasone group were significantly lower
comparedwith those in the placebo group (15 vs. 49%; P= 0.02).
As stated above, coadministration of anesthetic and other agents
during intrathecal chemotherapy administration may increase the risk
of emesis of intrathecal chemotherapy. Of the pediatric risk factors
identified for postoperative vomiting, twoare relevant in the context of
intrathecal chemotherapy administration: age greater than3 years and
history of postoperative vomiting in the patient, parent, or sibling.11
Since all patients in our population were older than 3 years and we did
not have information relating to familial history, we could not explore
these relationships.
The rate of complete acute CIV control observed in our study was
higher than has been reported in children receiving dexamethasone
or ondansetron prior to intrathecal chemotherapy administration. Dif-
ferences may be due, at least in part, to the anesthetic agent (e.g.,
propofol vs. ketamine). For example, propofol has a very low emetic
risk and is, therefore, the preferred anesthetic for patients at high risk
of postoperative vomiting.11 In addition, unlike other studies where
patients received a single ondansetron dose, several patients in our
study received more than one ondansetron dose during the acute
phase. The corticosteroid administered as part of the leukemia treat-
ment may also have conveyed an antiemetic effect. It is also possible
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that specific chemotherapy agents may be more or less emetogenic
thanMTX.
Interpretation of our study findings regarding CINV in the delayed
phase following IT-MTXadministration is limited by the administration
of PO chemotherapy during this period. Although the rates of vomiting
and nausea reflect the experience of our patients, symptoms are likely
attributable to both IT-MTX and PO chemotherapy. Furthermore, par-
ticipation in our study may have been subject to selection bias; it is
possible that patients may have been more or less apt to participate
depending on their prior experience with CINV.
In conclusion, acute phase CIV control in children receiving IT-MTX
with propofol anesthesia and ondansetron or granisetron is excellent.
Our study, the first to use a validated, pediatric, self-report measure to
evaluate nausea severity in children receiving intrathecal chemother-
apy, found that severe nausea is a common experience of children who
receive IT-MTX. Effective antinausea interventions must be identified
to optimize CINV control in children.
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